AAMI 10993 3 2014
$75.64
ANSI/AAMI/ISO 10993-3:2014 – Biological evaluation of medical devices-Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity
Published By | Publication Date | Number of Pages |
AAMI | 2014 | 50 |
Specifies strategies for hazard identification and tests on medical devices for genotoxicity, carcinogenicity, and reproductive and developmental toxicity. Applicable when the need to evaluate a medical device for potential genotoxicity, carcinogenicity, or reproductive toxicity has been established
PDF Catalog
PDF Pages | PDF Title |
---|---|
1 | ANSI/AAMI/ISO 10993-3:2014, Biological evaluation of medical devices—Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity |
3 | Title page |
4 | AAMI Standard Copyright information |
5 | Contents |
7 | Glossary of equivalent standards |
8 | Committee representation |
10 | Background of ANSI/AAMI adoption of ISO 10993-3:2014 |
11 | Foreword |
13 | Introduction Introduction |
15 | 1 Scope 2 Normative references |
16 | 3 Terms and definitions 4 Requirements for test strategies 4.1 General |
17 | 4.2 Additional requirements for carcinogenicity testing 4.3 Additional requirements for reproductive toxicity testing |
18 | 5 Genotoxicity tests 5.1 General 5.2 Test strategy 5.2.1 General 5.2.2 Test battery |
19 | 5.2.3 Follow-up evaluation |
20 | 5.3 Sample preparation |
21 | 6 Carcinogenicity tests 6.1 General 6.2 Evaluation strategy |
22 | 6.3 Sample preparation 6.4 Test methods |
23 | 7 Reproductive and developmental toxicity tests 7.1 General 7.2 Test strategy |
24 | 7.3 Sample preparation 7.4 Test methods 8 Test report |
26 | Annex A: Guidance on selecting an appropriate sample preparation procedure in genotoxicity testing A.1 General |
27 | A.2 Device materials A.2.1 Low Molecular Weight Chemicals (LMWC) A.2.2 Polymers (including naturally occurring polymers) A.2.2.1 LMWC contained in polymers A.2.2.2 Oligomers |
28 | A.2.2.3 Biodegradable polymers A.2.3 Inorganic materials: Wear debris from metals, alloys and ceramics A.3 Sample Preparation Methods A.3.1 General |
29 | Figure A.1 — Structured approach to select a sample preparation procedure |
30 | Table A.1 — Common extraction solvents A.3.2 Method A A.3.3 Method B A.3.3.1 General |
31 | A.3.3.2 Test sample preparation A.3.3.3 Procedure |
32 | A.3.3.4 Expression of results A.3.4 Method C A.3.4.1 General A.3.4.2 Procedure |
33 | A.4 Additional guidance on special sample preparation procedures A.4.1 Biodegradable polymers A.4.2 Inorganic materials: Wear debris from metals, alloys and ceramics A.4.3 LMWC |
34 | Annex B: Flowchart for follow-up evaluation Figure B.1 — Flowchart for follow-up evaluation |
35 | Annex C: Rationale of test systems C.1 Genotoxicity tests |
36 | C.2 Carcinogenicity tests C.3 Reproductive/developmental toxicity tests |
37 | Annex D: Cell transformation test systems |
38 | Annex E: Considerations for carcinogenicity studies performed as implantation studies E.1 Foreign body carcinogenesis E.2 Animal welfare considerations |
39 | Annex F: In vitro tests for embryo toxicity Table F.1 — Criteria defined by the management team of the study to evaluate test performance |
40 | Table F.2 — Summary of the classification results (all data[88]) |
41 | Annex ZA: Relationship between this European Standard and the Essential Requirements of EU Directive 93/42 EEC on medical devices Table ZA.1 — Correspondence between this European Standard and Directive 93/42/EEC on medical devices |
43 | Annex ZB: Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on active implantable medical devices Table ZB.1 — Correspondence between this European Standard and Directive 90/385/EEC on active implantable medical devices |
44 | Bibliography |